2023 annual financial data
Sutro Biopharma 2023 Operating cash flow margin
Direct answer
Operating cash flow margin was -72.6%.
Operating income was -89.28M USD and net income was -106.79M USD.
Operating cash flow was -111.62M USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 153.73M USD
- Operating income
- -89.28M USD
- Net income
- -106.79M USD
- Operating cash flow
- -111.62M USD